eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2023
vol. 18
 
Share:
Send email
Share:
abstract:
Original paper

Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis

Adnan Malik
1
,
Mahum Nadeem
2
,
Waseem Amjad
3
,
Muhammad Imran Malik
4
,
Sadia Javaid
5
,
Umer Farooq
6
,
Khadija Naseem
7
,
Ahmad Khan
8

  1. Saint Joseph's Medical Centre, Stockton, California, United States
  2. Oklahoma University Medical Centre, Oklahoma City, Oklahoma, United States
  3. Harvard Medical School, Boston, Massachusetts, United States
  4. Airedale General Hospital, West Yorkshire, England
  5. Nishtar Medical University Multan, Pakistan
  6. Macneal Hospital, Berwyn, Illinois, USA
  7. West Virginia Charleston Medical Centre, WV, USA
  8. Case Western Reserve University, Cleveland, Ohio, USA
Gastroenterology Rev 2023; 18 (1): 67–75
DOI: https://doi.org/10.5114/pg.2022.113573
Online publish date: 2022/02/17
View full text Get citation
 
PlumX metrics:
Introduction
Nonalcoholic fatty liver disease (NAFLD) comprises a wide range of related liver disorders affecting mainly people who drink no or very little alcohol. Aramchol is a new synthetic molecule that has been shown to reduce liver fat content. There is little evidence supporting its efficacy in humans.

Aim
To evaluate the efficacy of Aramchol in patients with NAFLD according to different randomized clinical trials.

Material and methods
We searched PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of Aramchol in patients with NAFLD. Risk of bias assessment was performed using Cochrane’s risk of bias tool. We included the following outcomes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), glycated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), HOMA-IR, and insulin level.

Results
We included 3 clinical trials. We found that the Aramchol group did not show any significant difference from the control group regarding ALT (MD = 3.92 (–21.20, 29.04), p = 0.76), AP (MD = –0.59 (–8.85, 7.67), p = 0.89), HbA1c (MD = –0.11 (–0.32, 0.10), p = 0.29), TC (MD = 14.25 (–626, 34.77), p = 0.17), TG (MD = 2.29 (–39.30, 43.87), p = 0.91), HOMA–IR (MD = –0.11 (–1.58, 1.37), p = 0.89), and insulin levels (MD = –0.88 (–5.82, 4.06), p = 0.73). AST levels were significantly higher in the Aramchol group (MD =11.04 (4.91, 17.16), p = 0.04).

Conclusions
Aramchol was a safe and tolerable drug to be used in patients with NAFLD. However, it was not superior to placebo in reducing the biochemical liver markers.

keywords:

non-alcoholic fatty liver disease, Aramchol, meta-analysis
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.